Go Pro
→ 1 Stock to Own by July 31st (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
$1.79
+4.7%		$1.53
$1.28
▼
$9.50
$60.20M1.778,798 shs72,496 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$14.36
+6.0%		$20.51
$7.78
▼
$34.10
$210.75M1.46242,223 shs150,860 shs
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
$1.36
+3.8%		$2.71
$0.92
▼
$8.69
$154.01M1.18468,346 shs104,934 shs
I-Mab stock logo
NBP
I-Mab
$1.65
+2.5%		$1.74
$1.46
▼
$6.79
$190.82M1.47792,763 shs250,173 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
+4.27%+11.76%+14.77%+18.75%-64.74%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+0.30%+0.74%-38.45%-39.28%+22.09%
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
+1.55%-35.78%-56.77%-37.32%-82.05%
I-Mab stock logo
NBP
I-Mab
+0.63%-9.55%-24.77%-32.35%+160,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
$1.79
+4.7%		$1.53
$1.28
▼
$9.50
$60.20M1.778,798 shs72,496 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$14.36
+6.0%		$20.51
$7.78
▼
$34.10
$210.75M1.46242,223 shs150,860 shs
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
$1.36
+3.8%		$2.71
$0.92
▼
$8.69
$154.01M1.18468,346 shs104,934 shs
I-Mab stock logo
NBP
I-Mab
$1.65
+2.5%		$1.74
$1.46
▼
$6.79
$190.82M1.47792,763 shs250,173 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
+4.27%+11.76%+14.77%+18.75%-64.74%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+0.30%+0.74%-38.45%-39.28%+22.09%
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
+1.55%-35.78%-56.77%-37.32%-82.05%
I-Mab stock logo
NBP
I-Mab
+0.63%-9.55%-24.77%-32.35%+160,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
2.00
Hold$12.00570.39% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.33
Hold$57.00297.05% Upside
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
1.00
SellN/AN/A
I-Mab stock logo
NBP
I-Mab
2.00
Hold$9.00445.45% Upside

Current Analyst Ratings Breakdown

Latest DWTX, NBP, INDP, and GLSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/21/2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$50.00 ➝ $69.00
7/17/2026
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/1/2026
I-Mab stock logo
NBP
I-Mab
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/19/2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$12.00
5/18/2026
I-Mab stock logo
NBP
I-Mab
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
5/15/2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
5/4/2026
I-Mab stock logo
NBP
I-Mab
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/AN/AN/AN/A$2.33 per shareN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.03 per shareN/A
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/A$1.40 per shareN/A
I-Mab stock logo
NBP
I-Mab
$3.89M49.05N/AN/A$2.00 per share0.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$34.26M-$10.60N/AN/AN/AN/A-108.57%-30.28%8/12/2026 (Estimated)
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$19.36M-$1.57N/AN/AN/AN/A-941.15%-368.53%8/13/2026 (Estimated)
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$20.85M-$15.40N/AN/AN/AN/A-1,030.07%-299.69%8/17/2026 (Estimated)
I-Mab stock logo
NBP
I-Mab
-$46.27M-$0.36N/AN/AN/AN/AN/AN/AN/A

Latest DWTX, NBP, INDP, and GLSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/17/2026Q2 2026
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$1.57N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.33N/AN/AN/AN/AN/A
8/12/2026Q2 2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$0.13N/AN/AN/AN/AN/A
5/15/2026Q1 2026
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$1.87-$0.23+$1.64-$0.23N/AN/A
5/14/2026Q1 2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$0.22-$0.15+$0.07-$0.15N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/AN/A
I-Mab stock logo
NBP
I-Mab
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/A
5.86
5.86
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
2.01
2.01
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/A
2.34
2.34
I-Mab stock logo
NBP
I-Mab
N/A
8.09
8.09

Institutional Ownership

CompanyInstitutional Ownership
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
9.05%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
7.06%
I-Mab stock logo
NBP
I-Mab
38.38%

Insider Ownership

CompanyInsider Ownership
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
0.30%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.47%
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
9.94%
I-Mab stock logo
NBP
I-Mab
22.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
533.63 million33.53 millionN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
314.68 million7.12 millionNot Optionable
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
6113.24 million101.99 millionNot Optionable
I-Mab stock logo
NBP
I-Mab
380115.65 million90.09 millionN/A

Recent News About These Companies

NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
July 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/24/3333120/0/en/novabridge-biosciences-to-hold-annual-general-meeting-on-september-8-2026.html
I-Mab (NASDAQ:NBP) Trading Down 4.9% – Time to Sell?
July 23, 2026  |  defenseworld.netD
I-Mab (NASDAQ:NBP) Trading Down 4.9% - Time to Sell?
July 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/i-mab-nasdaqnbp-trading-down-49-time-to-sell-2026-07-23/
NovaBridge: Rebranded, Repackaged, But Far From De-Risked
July 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4919853-novabridge-rebranded-repackaged-but-far-from-de-risked
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
June 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/29/3318837/0/en/novabridge-biosciences-appoints-dr-srishti-gupta-as-chief-executive-officer.html
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
June 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/16/3312417/0/en/novabridge-biosciences-receives-fda-fast-track-designation-for-givastomig-in-first-line-her2-negative-metastatic-gastric-cancer.html
Cong Claire Xu Sells 3,494 Shares of I-Mab (NASDAQ:NBP) Stock
June 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nbp-insider-buying-and-selling-2026-06-03/
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3302657/0/en/novabridge-to-present-at-the-2026-jefferies-global-healthcare-conference.html
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3292666/0/en/novabridge-to-present-at-the-h-c-wainwright-4th-annual-bioconnect-investor-conference.html
Mark Arnold Hagler Buys 230,000 Shares of I-Mab (NASDAQ:NBP) Stock
April 29, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nbp-insider-buying-and-selling-2026-04-29/
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3278829/0/en/novabridge-appoints-mark-hagler-as-president-and-chief-commercial-officer-to-advance-commercial-strategy-and-maximize-pipeline-value.html
NovaBridge's Givastomig Could Drive A Major Re-Rating
April 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4889454-novabridge-givastomig-could-drive-major-re-rating
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
April 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/07/3269679/0/en/NovaBridge-Reports-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
March 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/16/3256129/0/en/novabridge-announces-productive-fda-type-b-meeting-on-potential-accelerated-approval-pathway-for-givastomig-in-gastric-cancer.html
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
March 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/09/3251682/0/en/novabridge-and-visara-announce-positive-results-from-vis-101-phase-2a-wet-amd-study.html
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
March 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/03/3248489/0/en/novabridge-to-host-business-update-call-to-review-phase-2a-data-for-vis-101-in-wet-amd-on-monday-march-9-2026.html
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
March 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/02/3247232/0/en/novabridge-to-present-at-the-leerink-partners-2026-global-healthcare-conference.html
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
February 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/19/3240925/0/en/novabridge-appoints-biotech-leader-emmett-t-cunningham-jr-md-phd-mph-as-vice-chairman-of-the-board-to-further-accelerate-global-biotech-platform.html
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
February 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/17/3239738/0/en/novabridge-doses-first-patient-in-global-randomized-phase-2-study-of-givastomig-combined-with-immunochemotherapy-in-patients-with-1l-metastatic-gastric-cancer.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dogwood Therapeutics stock logo

Dogwood Therapeutics NASDAQ:DWTX

$1.79 +0.08 (+4.68%)
Closing price 04:00 PM Eastern
Extended Trading
$1.80 +0.01 (+0.84%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$14.36 +0.82 (+6.03%)
Closing price 03:59 PM Eastern
Extended Trading
$14.38 +0.02 (+0.17%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Indaptus Therapeutics stock logo

Indaptus Therapeutics NASDAQ:INDP

$1.36 +0.05 (+3.82%)
Closing price 04:00 PM Eastern
Extended Trading
$1.38 +0.02 (+1.84%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

I-Mab stock logo

I-Mab NASDAQ:NBP

$1.65 +0.04 (+2.48%)
Closing price 04:00 PM Eastern
Extended Trading
$1.64 0.00 (-0.30%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas